Invention Grant
US08741929B2 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
有权
使用3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮处理套细胞淋巴瘤的方法
- Patent Title: Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
- Patent Title (中): 使用3-（4-氨基-1-氧代-1,3-二氢 - 异吲哚-2-基） - 哌啶-2,6-二酮处理套细胞淋巴瘤的方法
-
Application No.: US12621502Application Date: 2009-11-19
-
Publication No.: US08741929B2Publication Date: 2014-06-03
- Inventor: Jerome B. Zeldis
- Applicant: Jerome B. Zeldis
- Applicant Address: US NJ Summit
- Assignee: Celgene Corporation
- Current Assignee: Celgene Corporation
- Current Assignee Address: US NJ Summit
- Agency: Jones Day
- Main IPC: A61K31/445
- IPC: A61K31/445
Abstract:
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
Public/Granted literature
Information query
IPC分类:
